- Home
- ITOS
as 05-30-2025 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 270.7M | IPO Year: | 2020 |
| Target Price: | $10.60 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.80 - $18.13 | Next Earning Date: | 04-28-2025 |
| Revenue: | $35,000,000 | Revenue Growth: | 177.89% |
| Revenue Growth (this year): | -78.43% | Revenue Growth (next year): | 31.74% |
Stock Insider Trading Activity of iTeos Therapeutics Inc. (ITOS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | ITOS | 10% Owner | May 14 '25 | Buy | $7.70 | 4,958,978 | $38,685,561.58 | 7,388,978 | |
| GADICKE ANSBERT | ITOS | N/A | May 13 '25 | Sell | $8.06 | 1,031,931 | $8,317,363.86 | 3,452,797 |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
2 days ago
iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
MT Newswires
3 days ago
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10
MT Newswires
3 days ago
iTeos Therapeutics to Wind Down Operations
GlobeNewswire
3 days ago
iTeos Therapeutics Announces Its Intention to Wind Down Operations
BioPharma Dive
3 days ago
Cancer drugmaker iTeos to shut down
MT Newswires
16 days ago
Iteos Therapeutics Insider Sold Shares Worth $8,317,364, According to a Recent SEC Filing
Zacks
16 days ago
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
MT Newswires
17 days ago
Leerink Downgrades iTeos Therapeutics to Market Perform From Outperform
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.